Liquidia (LQDA) Insider Krepp Sarah Sells $149K of Stock

Krepp Sarah, Chief Human Resource Officer at Liquidia Corporation, sold 5,245 shares on October 12, 2026, for approximately $149,378. This sale was part of a planned transaction, priced at $28.48 per share.

Other Institutional Activity in Liquidia Corporation

Blackrock Inc. grew its holdings by 5,299,329 shares, ending with 10,788,586 shares worth about $370.6 million. Vanguard Capital Management LLC added 212,206 shares, bringing their total to 3,139,183 shares valued at approximately $107.8 million. Meanwhile, Farallon Capital Management LLC trimmed its stake by 290,837 shares, resulting in 8,365,038 shares worth about $287.3 million.

Liquidia Corporation Stock Down 2.9%

Liquidia's stock recently traded around $33.77, which is below its 50-day moving average of $61.62 and its 200-day average of $53.93. The shares are also down about 63.9% from their 52-week high of $93.61, while remaining 53.9% above the 52-week low of $21.94.

Recent Earnings

For the trailing twelve months, Liquidia reported revenue of $450.9 million and earnings per share (EPS) of $1.39. The company has shown impressive growth with a year-over-year revenue growth of 1,842.7%. Their next earnings report is set for November 3, 2026.

Insider Buying and Selling at Liquidia Corporation

On the same day as Krepp's sale, several other insiders also sold shares. Dana Boyle, an officer, sold 5,892 shares at $28.48, totaling $167,804. Sanjeev Khindri, another officer, sold 1,101 shares for $31,356, while Chief Operating Officer Michael Kaseta sold 18,938 shares for $539,354. Jason Adair, an officer, sold 7,301 shares, bringing in $207,932.

Analysts Set New Price Targets

On October 1, 2026, Raymond James downgraded Liquidia to an 'Outperform' rating with a new price target of $53.00, down from $106.00. BTIG also downgraded the stock to 'Neutral'. Meanwhile, Needham maintained a 'Buy' rating with a target of $72.00, and Wells Fargo set a target of $30.00 while downgrading to 'Equal-Weight'. The consensus among analysts is a 'buy' rating with a mean price target of $54.38.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, NC. It focuses on developing products for rare cardiopulmonary diseases in the U.S. Its lead product candidate, YUTREPIA, is designed for treating pulmonary arterial hypertension and related conditions. This insider sale comes amid a backdrop of mixed analyst ratings and a significant drop in stock price from its highs.

Bottom Line

Investors should keep an eye on Liquidia's upcoming earnings report on November 3, 2026, and monitor any further insider trading activity. The recent sale by Krepp Sarah, alongside other insider transactions, may suggest varying confidence levels among Liquidia's leadership amid recent stock price volatility.